Iambic Therapeutics (IAM) Director Rachlin Buys $12M of Stock
Key Points
- Director Evan Lockwood Rachlin purchased 718,750 shares of Iambic Therapeutics, Inc. on October 16, 2026, for a total value of $11.5 million.
- The purchase lifted the director's total holdings to 2,588,248 shares, marking a 38.5% increase in his position.
- Iambic Therapeutics recently traded around $16.34 per share as of October 20, 2026, sitting below its 50-day moving average.
Get Iambic Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $IAM.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Iambic Therapeutics, Inc. alert may contain errors. Disclosures
Director Evan Lockwood Rachlin bought 718,750 shares of Iambic Therapeutics, Inc. (IAM) on October 16, 2026. According to a Form 4 filing with the Securities and Exchange Commission, the transaction took place at a price of $16.00 per share, coming out to a total value of $11.5 million.
IAM
Iambic Therapeutics, Inc.
Inside Evan Lockwood Rachlin's Iambic Therapeutics Trade
The purchase expanded the director's direct holdings to 2,588,248 shares. This acquisition marked a 38.5% increase in his overall stake in the biotechnology firm. The trade was executed directly by the insider and was not made under a pre-arranged Rule 10b5-1 trading plan.
Iambic Therapeutics, Inc. Stock Down 31.4%
Shares of Iambic Therapeutics recently traded around $16.34 as of October 20, 2026. The stock sits below its 50-day moving average of $21.36 and below its 52-week high of $25.00, while holding above its 52-week low of $14.10.
Recent Earnings
For the trailing twelve months, Iambic Therapeutics posted revenue of $18.3 million alongside basic earnings per share of -$2.69. The company does not currently have a meaningful price-to-earnings ratio because it is not profitable.
About Iambic Therapeutics
Iambic Therapeutics, Inc. is a San Diego-based biotechnology company with 171 employees. The firm develops medicines using an artificial intelligence discovery platform designed to optimize target product profiles and drug candidates.
Bottom Line
This sizable insider purchase brings significant attention to the biotech firm's leadership activity. Investors typically track large open-market buys by directors to gauge insider sentiment alongside upcoming earnings reports.
Related Filing Alerts
Source: Evan Lockwood Rachlin's Form 4 filing on $IAM (Oct 16, 2026). Written by software, not financial advice. How we make alerts